Genfit S.A. (NASDAQ:GNFT) Sees Significant Increase in Short Interest

Genfit S.A. (NASDAQ:GNFT) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 67,800 shares, a growth of 16.5% from the September 15th total of 58,200 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 10,700 shares, the short-interest ratio is currently 6.3 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, October 11th.

Genfit Trading Up 6.3 %

Shares of NASDAQ:GNFT traded up $0.37 during midday trading on Wednesday, reaching $6.28. 35,695 shares of the company’s stock traded hands, compared to its average volume of 17,429. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a one year low of $2.97 and a one year high of $6.29. The stock has a 50 day moving average of $4.66 and a 200 day moving average of $4.30.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.